Novartis agreed to acquire Synnovation’s Pikavation subsidiary for $2 billion up front to secure SNV4818, a pan‑mutant‑selective PI3Kα inhibitor in phase II/II testing for HR+/HER2‑ metastatic breast cancer and other solid tumors. Novartis framed the buy as a precision‑medicine add to its breast‑cancer portfolio that could pair with endocrine and CDK inhibitor regimens. Synnovation will retain other assets and continue independent R&D while Novartis assumes global development and commercialization duties for the PI3Kα program.